Placebo IM

DRUG5 trials

Sponsors

Alexza Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, AstraZeneca, Gates Medical Research Institute, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Coronavirus Disease 2019 (COVID-19)Cytomegalovirus InfectionsHealthy VolunteerHealthy VolunteersHumanInfluenza

Phase 1

Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)

CompletedNCT01986010

Merck Sharp & Dohme LLCCytomegalovirus Infections

Start: 2013-11-25End: 2017-03-14Updated: 2021-11-01

A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults

CompletedNCT05437289

AstraZenecaCoronavirus Disease 2019 (COVID-19), Healthy Volunteer

Start: 2021-10-09End: 2023-01-16Updated: 2023-03-31

Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

CompletedNCT06408857

Gates Medical Research InstituteHealthy Volunteers

Start: 2025-03-28End: 2026-05-28Updated: 2026-06-03

Phase 2

BPL-1357 Against H1N1 Influenza Virus Challenge

RecruitingNCT07215858

National Institute of Allergy and Infectious Diseases (NIAID)Human, Influenza

Start: 2026-09-23End: 2028-03-01Target: 129Updated: 2026-09-18

Phase 4

ADASUVE-Lorazepam Drug-Drug Interaction

CompletedNCT01877642

Alexza Pharmaceuticals, Inc.Healthy Volunteers

Start: 2013-06-30End: 2013-07-31Updated: 2017-12-13

Related Papers

A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial.

2021-06-0224 citations

Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus Vaccine

The Journal of Infectious Diseases2020-10-0110 citations

Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects

The Journal of Infectious Diseases2019-04-1171 citations